Paper42878985PubMed
GLP-1 Receptor Agonists and Lipoprotein (a): Insights, Gaps and Clinical Implications in Cardiovascular Diseases.
Mikhael FG and 6 others. Curr Atheroscler Rep, 2026.
Cite this record
ConductScience Library. GLP-1 Receptor Agonists and Lipoprotein (a): Insights, Gaps and Clinical Implications in Cardiovascular Diseases. Papers, record 42878985. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42878985
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- GLP-1 Receptor Agonists and Lipoprotein (a): Insights, Gaps and Clinical Implications in Cardiovascular Diseases.
- Journal
- Curr Atheroscler Rep
- Year
- 2026
- Publication types
- Journal Article, Review
- Revised in PubMed
- 2026-11-05
Source PubMed
Topics7
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Cardiovascular Diseases | Major topic |
| Glucagon-Like Peptide-1 Receptor Agonists | Major topic |
| Lipoprotein(a) | Major topic |
| Hypoglycemic Agents | Major topic |
| Humans | |
| Animals | |
| Biomarkers |
Source PubMed
Grants2
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| Scholarly Concentration Track | Faculty of Medicine, American University of Beirut | PubMed | ||
| University Research Board (URB)-103949; URB-104262; URB-104115; URB-104524; Medical Practice Plan (MPP)-320145 | Faculty of Medicine, American University of Beirut | PubMed |
Source PubMed
References93
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 32268367 | Potent lipoprotein(a) lowering following apolipoprotein(a) antisense treatment reduces the pro-inflammatory activation of circulating monocytes in patients with elevated lipoprotein(a). | Eur Heart J | 2020 | https://conductscience.org/library/papers/32268367 | PubMed |
| 2 | 22284365 | The glucagon-like peptide 1 analog liraglutide reduces TNF-α-induced oxidative stress and inflammation in endothelial cells. | Atherosclerosis | 2012 | https://conductscience.org/library/papers/22284365 | PubMed |
| 3 | 27345422 | The Cardiovascular Biology of Glucagon-like Peptide-1. | Cell Metab | 2016 | https://conductscience.org/library/papers/27345422 | PubMed |
| 4 | 20225248 | Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway. | Hepatology | 2010 | https://conductscience.org/library/papers/20225248 | PubMed |
| 5 | 35229024 | Treatment with glucagon-like peptide-1 receptor agonists and incidence of dementia: Data from pooled double-blind randomized controlled trials and nationwide disease and prescription registers. | Alzheimers Dement (N Y) | 2022 | https://conductscience.org/library/papers/35229024 | PubMed |
| 6 | 40781022 | Pelacarsen: Mechanism of action and Lp(a)-lowering effect. | J Clin Lipidol | 2025 | https://conductscience.org/library/papers/40781022 | PubMed |
| 7 | 35140289 | Exendin-4 alleviates steatosis in an in vitro cell model by lowering FABP1 and FOXA1 expression via the Wnt/-catenin signaling pathway. | Sci Rep | 2022 | https://conductscience.org/library/papers/35140289 | PubMed |
| 8 | 25014686 | Effects of extended-release niacin with laropiprant in high-risk patients. | N Engl J Med | 2014 | https://conductscience.org/library/papers/25014686 | PubMed |
| 9 | 41158620 | GLP-1 receptor agonists synergistic effects of metabolic reprogramming and cardioprotection. | Front Endocrinol (Lausanne) | 2025 | https://conductscience.org/library/papers/41158620 | PubMed |
| 10 | 36977782 | Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action. | Nat Rev Cardiol | 2023 | https://conductscience.org/library/papers/36977782 | PubMed |
| 11 | 34098057 | Effect of glucagon-like peptide-1 receptor agonists on circulating levels of leptin and resistin: A meta-analysis of randomized controlled trials. | Diabetes Res Clin Pract | 2021 | https://conductscience.org/library/papers/34098057 | PubMed |
| 12 | 31965072 | Liraglutide improves memory in obese patients with prediabetes or early type 2 diabetes: a randomized, controlled study. | Int J Obes (Lond) | 2020 | https://conductscience.org/library/papers/31965072 | PubMed |
| 13 | 21145820 | Glucagon-like peptide-1 reduces hepatic lipogenesis via activation of AMP-activated protein kinase. | J Hepatol | 2011 | https://conductscience.org/library/papers/21145820 | PubMed |
| 14 | 36813656 | Effects of bempedoic acid on CRP, IL-6, fibrinogen and lipoprotein(a) in patients with residual inflammatory risk: A secondary analysis of the CLEAR harmony trial. | J Clin Lipidol | 2023 | https://conductscience.org/library/papers/36813656 | PubMed |
| 15 | 38832475 | Lipid profile changes induced by glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a systematic review and network meta-analysis. | Expert Rev Clin Pharmacol | 2024 | https://conductscience.org/library/papers/38832475 | PubMed |
| 16 | 41086442 | Anti-inflammatory properties of GLP-1 receptor agonists and other ancillary benefits from a pharmacological perspective. | Can J Physiol Pharmacol | 2025 | https://conductscience.org/library/papers/41086442 | PubMed |
| 17 | 37794465 | Chronic kidney outcomes associated with GLP-1 receptor agonists versus long-acting insulins among type 2 diabetes patients requiring intensive glycemic control: a nationwide cohort study. | Cardiovasc Diabetol | 2023 | https://conductscience.org/library/papers/37794465 | PubMed |
| 18 | 23973688 | Relationship of apolipoproteins A-1 and B, and lipoprotein(a) to cardiovascular outcomes: the AIM-HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglyceride and Impact on Global Health Outcomes). | J Am Coll Cardiol | 2013 | https://conductscience.org/library/papers/23973688 | PubMed |
| 19 | 36005135 | Liraglutide Exerts Protective Effects by Downregulation of PPARγ, ACSL1 and SREBP-1c in Huh7 Cell Culture Models of Non-Alcoholic Steatosis and Drug-Induced Steatosis. | Curr Issues Mol Biol | 2022 | https://conductscience.org/library/papers/36005135 | PubMed |
| 20 | 35637990 | Effects of novel glucose-lowering drugs on the lipid parameters: A systematic review and meta-analysis. | Ann Med Surg (Lond) | 2022 | https://conductscience.org/library/papers/35637990 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Cited by
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42878985
GET https://conductscience.org/api/papers/v1/42878985/references?page=2